News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Grant Life Sciences (GLIF.OB) Enters Into Memorandum Of Understanding -MOU- To License Point-Of-Care -POC- Diagnostic Platform From AccuDx Inc.


10/19/2005 5:12:33 PM

RALEIGH, N.C.--(BUSINESS WIRE)--Jan. 25, 2005-- Under proposed terms, Grant Life Sciences will control exclusive rights to rapid tests for HIV-1, HIV-2 and Dengue Fever, as well as a proprietary colloidal gold reagent, a key ingredient commonly used by leading manufacturers of rapid tests as a detectable label

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES